Skip to main content
. 2023 May 15;29(15):2869–2884. doi: 10.1158/1078-0432.CCR-22-3567

Figure 3.

Figure 3. TMB and CNV in RIS compared with those in primary sarcomas. A, Heat maps for mutated genes in important pathways in the RIS group and the SARC group. NOS, not otherwise specified. B and C, COSMIC mutational signature analysis and nucleotide change type analysis (C) of RIS and primary sarcomas. D, TMB in RIS and primary sarcomas, including comparison between subtypes. The numbers in the plot indicate mean value. E, The predicted total tumor neoantigen burden (left) and the predicted strong binding neoantigen counts (right) in the RIS group and the SARC group. The numbers in the plot indicate mean value. Error bars indicate mean ± SD. ****, P < 0.0001.

TMB and CNV in RIS compared with those in primary sarcomas. A, Heat maps for mutated genes in important pathways in the RIS group and the SARC group. NOS, not otherwise specified. B and C, COSMIC mutational signature analysis and nucleotide change type analysis (C) of RIS and primary sarcomas. D, TMB in RIS and primary sarcomas, including comparison between subtypes. The numbers in the plot indicate mean value. E, The predicted total tumor neoantigen burden (left) and the predicted strong binding neoantigen counts (right) in the RIS group and the SARC group. The numbers in the plot indicate mean value. Error bars indicate mean ± SD. ****, P < 0.0001.